Eurofins Genomics US Expands Gene Synthesis Capabilities

Eurofins Genomics LLC (US) has acquired Blue Heron Biotech, a company specializing in advanced gene synthesis. The acquisition provides synergies for both companies due to the inherent connection between their main product segments—oligonucleotides, sequencing and synthetic genes, and strengthens Eurofins Genomics offer in the synthetic biology market.
 
Blue Heron is known for their expertise in gene synthesis and sub cloning, which allows them to construct sizable gene constructs. Since DNA oligonucleotides play an integral role in genes, the deal will bolster Blue Heron's production capabilities as well as expand Eurofins Genomics gene portfolio into cloning and complex gene constructs.
 
Eurofins Genomics is a global provider of oligonucleotide synthesis, Sanger sequencing, next generation sequencing, and gene synthesis.
 
The announcement is especially interesting to researchers in the synthetic biology and diagnostic sectors, which require large volumes of both genes and oligonucleotides. Eurofins Genomics is now positioned to provide holistic solutions to these customers. It even offers regulatory coverage for its products, including ISO 13485, ISO 9001, CLIA, CAP, GLP, and FDA compliance for the manufacturing of cGMP oligonucleotides used in ASR and IVD products for the clinical industry.

-----------------------------------------------------------------------
Editor's Note:

If you have any suggestion to the content, 

please email: Julia.Zhang@ubmsinoexpo.com